Source facts
FDA issued an approval letter for LEQSELVI on 2026-07-02. The source metadata identifies NDA 217900 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
LEQSELVI — FDA Approval Letter (NDA 217900)
Issued to SUN PHARM INDS INC. Application is approved as submitted.
Issued
July 2, 2026Application
NDA 505b1 • 217900
Product
LEQSELVI
Company
SUN PHARM INDS INC
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for LEQSELVI?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 217900.
- 3Submission: supplement.
- 4Sponsor: SUN PHARM INDS INC.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the LEQSELVI approval letter
Is LEQSELVI FDA approved?
This letter documents an FDA approval action: FDA approved NDA 217900 for LEQSELVI, sponsored by SUN PHARM INDS INC, on July 2, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 217900?
NDA 217900 is the application under which FDA issued this approval letter for LEQSELVI to SUN PHARM INDS INC. The letter is dated July 2, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.